Sanofi faces French charges in Depakine birth defects probe
admin 4th February 2020 Uncategorised 0French authorities have spent more than three years investigating whether Sanofi downplayed the danger of birth defects linked to its valproate-based anti-epilepsy med Depakine. Now, that probe has materialized into actual charges—but it might not land Sanofi in the courtroom.
More: Sanofi faces French charges in Depakine birth defects probe
Source: fierce